Nurix Therapeutics (NASDAQ:NRIX) Price Target Raised to $36.00 at Stifel Nicolaus

Nurix Therapeutics (NASDAQ:NRIX) had its target price upped by Stifel Nicolaus from $34.00 to $36.00 in a report released on Wednesday,Benzinga reports. The brokerage currently has a buy rating on the stock.

Several other equities research analysts have also weighed in on NRIX. Jefferies Financial Group began coverage on Nurix Therapeutics in a research report on Friday, October 11th. They set a “buy” rating and a $41.00 target price on the stock. Needham & Company LLC restated a “buy” rating and issued a $29.00 target price on shares of Nurix Therapeutics in a research note on Tuesday, December 10th. Stephens restated an “overweight” rating and issued a $31.00 target price on shares of Nurix Therapeutics in a research note on Tuesday, January 21st. BMO Capital Markets assumed coverage on shares of Nurix Therapeutics in a research note on Friday, December 6th. They issued an “outperform” rating and a $35.00 price objective for the company. Finally, UBS Group began coverage on shares of Nurix Therapeutics in a research report on Thursday, October 24th. They set a “buy” rating and a $35.00 target price for the company. One investment analyst has rated the stock with a hold rating and sixteen have given a buy rating to the stock. According to MarketBeat.com, the stock presently has an average rating of “Moderate Buy” and a consensus target price of $30.71.

Nurix Therapeutics Price Performance

NASDAQ NRIX opened at $19.65 on Wednesday. Nurix Therapeutics has a one year low of $7.79 and a one year high of $29.56. The business has a fifty day moving average price of $20.20 and a 200 day moving average price of $22.42.

Nurix Therapeutics (NASDAQ:NRIX) last released its quarterly earnings results on Tuesday, January 28th. The company reported ($0.75) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.67) by ($0.08). Nurix Therapeutics had a negative return on equity of 63.39% and a negative net margin of 313.65%. On average, equities research analysts expect that Nurix Therapeutics will post -2.81 earnings per share for the current fiscal year.

Insider Activity at Nurix Therapeutics

In related news, CFO Houte Hans Van sold 3,546 shares of the company’s stock in a transaction dated Friday, November 1st. The shares were sold at an average price of $24.28, for a total transaction of $86,096.88. Following the transaction, the chief financial officer now owns 33,724 shares in the company, valued at $818,818.72. This represents a 9.51 % decrease in their position. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available at the SEC website. Insiders own 7.20% of the company’s stock.

Institutional Trading of Nurix Therapeutics

Several institutional investors and hedge funds have recently added to or reduced their stakes in the company. Amalgamated Bank increased its stake in shares of Nurix Therapeutics by 30.6% in the 3rd quarter. Amalgamated Bank now owns 2,182 shares of the company’s stock valued at $49,000 after acquiring an additional 511 shares during the last quarter. Mirae Asset Global Investments Co. Ltd. boosted its holdings in shares of Nurix Therapeutics by 31.6% in the 3rd quarter. Mirae Asset Global Investments Co. Ltd. now owns 2,330 shares of the company’s stock valued at $54,000 after buying an additional 559 shares during the last quarter. Quest Partners LLC boosted its holdings in shares of Nurix Therapeutics by 21.3% in the 3rd quarter. Quest Partners LLC now owns 7,458 shares of the company’s stock valued at $168,000 after buying an additional 1,312 shares during the last quarter. Teachers Retirement System of The State of Kentucky raised its stake in Nurix Therapeutics by 8.4% in the 3rd quarter. Teachers Retirement System of The State of Kentucky now owns 30,024 shares of the company’s stock valued at $675,000 after acquiring an additional 2,329 shares during the period. Finally, Quarry LP raised its stake in Nurix Therapeutics by 3,746.2% in the 3rd quarter. Quarry LP now owns 2,500 shares of the company’s stock valued at $56,000 after acquiring an additional 2,435 shares during the period.

Nurix Therapeutics Company Profile

Nurix Therapeutics, Inc, a clinical stage biopharmaceutical company, focuses on the discovery, development, and commercialization of small molecule and cell therapies for the treatment of cancer, inflammatory conditions, and other diseases. The company develops NX-2127, an orally bioavailable Bruton's tyrosine kinase (BTK) degrader for the treatment of relapsed or refractory B-cell malignancies; NX-5948, an orally bioavailable BTK degrader for the treatment of relapsed or refractory B-cell malignancies and autoimmune diseases; and NX-1607, an orally bioavailable Casitas B-lineage lymphoma proto-oncogene-B (CBL-B) inhibitor for immuno-oncology indications.